loading
Tango Therapeutics Inc stock is traded at $7.25, with a volume of 1.30M. It is down -3.54% in the last 24 hours and down -15.24% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$7.495
Open:
$7.48
24h Volume:
1.30M
Relative Volume:
0.50
Market Cap:
$806.64M
Revenue:
$24.30M
Net Income/Loss:
$-145.57M
P/E Ratio:
-5.4511
EPS:
-1.33
Net Cash Flow:
$-149.17M
1W Performance:
-20.98%
1M Performance:
-15.24%
6M Performance:
+395.21%
1Y Performance:
+21.92%
1-Day Range:
Value
$7.125
$7.70
1-Week Range:
Value
$6.69
$9.39
52-Week Range:
Value
$1.03
$9.70

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name
Name
Tango Therapeutics Inc
Name
Phone
(857) 320-4900
Name
Address
201 BROOKLINE AVENUE, BOSTON
Name
Employee
155
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
TNGX's Discussions on Twitter

Compare TNGX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TNGX
Tango Therapeutics Inc
7.25 1.00B 24.30M -145.57M -149.17M -1.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
420.57 108.04B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
475.81 60.75B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
583.26 61.26B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
825.21 50.32B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
316.55 34.14B 4.56B -176.77M 225.30M -1.7177

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-19-25 Initiated Piper Sandler Overweight
Jul-17-24 Initiated Jefferies Buy
Apr-04-24 Initiated Cantor Fitzgerald Overweight
Feb-12-24 Initiated Piper Sandler Overweight
Dec-08-23 Initiated B. Riley Securities Buy
Oct-20-22 Upgrade H.C. Wainwright Neutral → Buy
Sep-20-21 Initiated SVB Leerink Outperform
View All

Tango Therapeutics Inc Stock (TNGX) Latest News

pulisher
08:22 AM

Tango Therapeutics stock gains as Cantor Fitzgerald reiterates Overweight rating - Investing.com

08:22 AM
pulisher
07:34 AM

How to build a dashboard for Tango Therapeutics Inc. stockJuly 2025 Selloffs & Low Drawdown Investment Strategies - newser.com

07:34 AM
pulisher
06:11 AM

Is Tango Therapeutics Inc. stock entering bullish territoryChart Signals & High Conviction Buy Zone Picks - newser.com

06:11 AM
pulisher
05:46 AM

Tango Therapeutics Inc. stock trend outlook and recovery pathWeekly Profit Analysis & Trade Opportunity Analysis Reports - newser.com

05:46 AM
pulisher
04:19 AM

Ranking Tango Therapeutics Inc. among high performing stocks via toolsJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com

04:19 AM
pulisher
02:49 AM

Why Tango Therapeutics Inc. stock is trending among retail tradersMarket Sentiment Summary & Technical Entry and Exit Tips - newser.com

02:49 AM
pulisher
12:27 PM

Using AI based signals to follow Tango Therapeutics Inc.2025 Market Outlook & Proven Capital Preservation Tips - newser.com

12:27 PM
pulisher
Oct 26, 2025

Multi asset correlation models including Tango Therapeutics Inc.2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com

Oct 26, 2025
pulisher
Oct 24, 2025

Tango Therapeutics Inc. (TNGX) Stock Price | Live Quotes & Charts | NSD - StocksToTrade

Oct 24, 2025
pulisher
Oct 24, 2025

Guggenheim Maintains Tango Therapeutics (TNGX) Buy Recommendation - Nasdaq

Oct 24, 2025
pulisher
Oct 24, 2025

Guggenheim Maintains Buy Rating and Raises Price Target for TNGX - GuruFocus

Oct 24, 2025
pulisher
Oct 24, 2025

What analysts say about Tango Therapeutics Inc stockHigh Yield Income Stocks & Low Risk Trading Plans - earlytimes.in

Oct 24, 2025
pulisher
Oct 24, 2025

Guggenheim raises Tango Therapeutics stock price target on promising cancer drug data - Investing.com

Oct 24, 2025
pulisher
Oct 24, 2025

Tango Therapeutics price target raised to $12 from $10 at Guggenheim - TipRanks

Oct 24, 2025
pulisher
Oct 24, 2025

Tango Therapeutics announces $225 million financing - The Pharma Letter

Oct 24, 2025
pulisher
Oct 24, 2025

Form 424B5 Tango Therapeutics, Inc. - StreetInsider

Oct 24, 2025
pulisher
Oct 24, 2025

Tango Therapeutics prices $210 million stock offering By Investing.com - Investing.com Nigeria

Oct 24, 2025

Tango Therapeutics Inc Stock (TNGX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Tango Therapeutics Inc Stock (TNGX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Third Rock Ventures IV, L.P.
10% Owner
Sep 25 '25
Sale
8.02
500,000
4,008,500
13,863,975
$37.15
price down icon 0.41%
$91.76
price up icon 0.53%
$29.16
price down icon 2.64%
$105.21
price down icon 0.37%
$162.05
price up icon 1.56%
biotechnology ONC
$316.55
price up icon 1.88%
Cap:     |  Volume (24h):